The View host Joy Behar has sparked curiosity and raised some eyebrows with her recent revelation about the side effects of her weight loss medication, Ozempic. In a recent episode, Behar shared a bizarre and unexpected consequence of her weight loss journey: a newfound aversion to seafood.
Behar, who has lost 25 pounds since starting Ozempic, discovered that her sense of taste had undergone a peculiar transformation. She now finds herself unable to enjoy seafood, regardless of whether it's fresh or canned. This revelation came as a surprise to her co-hosts, especially considering the limited clinical research on this specific side effect.
The potential link between GLP-1 drugs and taste alterations is an intriguing one. Studies suggest that glucagon-like peptide-1 receptor agonists, like Ozempic, may not only suppress appetite but also impact taste buds. This could explain why Behar and others have reported a metallic taste in their food after taking these medications.
One Reddit thread, aptly titled 'Ozempic Ruined My Love For Tinned Fish,' further supports this claim. Multiple users shared their experiences of losing their appetite for canned fish, with some describing a metallic taste. This trend suggests that the impact on taste may be more widespread than initially thought.
Behar's revelation also coincided with a discussion about a study confirming that lobsters feel pain when boiled alive. She humorously noted that she was 'off the hook' when it came to her seafood aversion, as her co-host Sunny Hostin, who also takes GLP-1 drugs, still enjoys lobster.
Whoopi Goldberg, another co-host, offered a different reason for her avoidance of lobster, citing a past incident where her food was not properly cooked. This diversity in reasons for seafood aversion adds an interesting layer to the conversation.
The implications of these side effects are worth exploring further. While weight loss is often the primary goal of such medications, the impact on taste and food preferences could have significant psychological and social consequences. It raises questions about the potential long-term effects of these drugs on individuals' dietary habits and overall well-being.
In conclusion, Joy Behar's revelation about her seafood aversion is a fascinating and unexpected twist in the story of Ozempic. It highlights the importance of considering the broader implications of medical treatments and the potential for unforeseen side effects. As research continues, it will be crucial to understand the full scope of these medications' impact on taste and beyond.
